147 related articles for article (PubMed ID: 11098484)
41. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
[TBL] [Abstract][Full Text] [Related]
42. [Innate resistance to thymidylate synthase inhibition after 5-fluorouracil treatment--a rationale of combined use of cisplatin and its optimal administration dose].
Omura K; Hashimoto T; Kawakami K; Kanehira E; Watanabe T; Hirano K; Watanabe S; Watanabe Y; Shirasaka T
Gan To Kagaku Ryoho; 1994 Sep; 21(12):2007-11. PubMed ID: 8085851
[TBL] [Abstract][Full Text] [Related]
43. UFT/leucovorin vs 5-FU/leucovorin in colon cancer.
Smith RE; Lembersky BC; Wieand HS; Colangelo L; Mamounas EP
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):24-7. PubMed ID: 11098486
[TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors.
Peters GJ; Noordhuis P; Van Kuilenburg AB; Schornagel JH; Gall H; Turner SL; Swart MS; Voorn D; Van Gennip AH; Wanders J; Holwerda U; Smid K; Giaccone G; Fumoleau P; Van Groeningen CJ
Cancer Chemother Pharmacol; 2003 Jul; 52(1):1-12. PubMed ID: 12739060
[TBL] [Abstract][Full Text] [Related]
45. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
46. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
[TBL] [Abstract][Full Text] [Related]
47. [Intravenous continuous infusion of fluorouracil for treatment of metastatic colorectal cancer].
Hosokawa A
Nihon Rinsho; 2003 Sep; 61 Suppl 7():352-5. PubMed ID: 14574911
[No Abstract] [Full Text] [Related]
48. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil?
Jones R; Twelves C
Expert Opin Pharmacother; 2001 Sep; 2(9):1495-505. PubMed ID: 11585027
[TBL] [Abstract][Full Text] [Related]
49. The oral fluorouracil prodrugs.
Pazdur R; Hoff PM; Medgyesy D; Royce M; Brito R
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):48-51. PubMed ID: 9830626
[TBL] [Abstract][Full Text] [Related]
50. Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT).
Morio A; Miyamoto H; Izumi H; Futagawa T; Oh T; Yamazaki A; Konno H
Surg Today; 2004; 34(10):822-7. PubMed ID: 15449150
[TBL] [Abstract][Full Text] [Related]
51. [Concentration of 5-fluorouracil in the blood and tissues of gastric and colo-rectal cancer patients after oral administration of UFT].
Inaba S; Kondo Y; Tsuchiya K; Kawai K; Ogino A; Umeda T; Ueda Y
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2175-80. PubMed ID: 1444483
[TBL] [Abstract][Full Text] [Related]
52. [Pharmacokinetics of S-1].
Hirata K; Horikoshi N; Tominaga K; Sohma K; Yamaguchi K; Okazaki M; Furuhata T; Sasaki K; Nakano Y; Ishizuka H; Yamada Y; Uno S; Taguchi T; Yamamitsu S; Shirasaka T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():27-35. PubMed ID: 16897969
[TBL] [Abstract][Full Text] [Related]
53. Postoperative radiation therapy for rectal cancer combined with UFT/leucovorin.
Rosenthal DI; Haller DG; Saltz L; Semple D; Minsky BD
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):59-62. PubMed ID: 11098496
[TBL] [Abstract][Full Text] [Related]
54. [Concentration of 5-FU and tegafur in the ascites fluid in patients with peritonitis carcinomatosa after UFT oral administration].
Seki H; Takahashi H; Kimura K
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):747-8. PubMed ID: 3103545
[No Abstract] [Full Text] [Related]
55. [Blood and tumor levels of tegafur, 5-fluorouracil, and uracil].
Takeshita T; Iwasaki M; Narita M; Sou M; Sato M; Hashimoto T; Kameya S; Iigima N
Gan To Kagaku Ryoho; 1988 Nov; 15(11):3053-8. PubMed ID: 3142365
[TBL] [Abstract][Full Text] [Related]
56. 5-Fluorouracil and UFT-sensitive gastric carcinoma has a high level of thymidylate synthase.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sakaguchi Y; Kido Y; Okamura T; Korenaga D; Sugimachi K
Cancer; 1989 May; 63(9):1693-6. PubMed ID: 2495166
[TBL] [Abstract][Full Text] [Related]
57. Correct fluorouracil (5-FU) half-life comparator for a 5-FU prodrug plus a dihydropyrimidine dehydrogenase inhibitor.
White RM
J Clin Oncol; 2001 Jun; 19(11):2970. PubMed ID: 11387375
[No Abstract] [Full Text] [Related]
58. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
59. [The serum and tissue concentration of FT-207, 5'-DFUR and 5-FU in patients with breast cancer by preoperative administration of UFT and 5'-DFUR].
Kosaka A; Sumiyoshi K; Ando J
Gan To Kagaku Ryoho; 1989 Feb; 16(2):277-80. PubMed ID: 2521996
[No Abstract] [Full Text] [Related]
60. Effect of gastrectomy on the pharmacokinetics of tegafur, uracil, and 5-fluorouracil after oral administration of a 1:4 tegafur and uracil combination.
Maehara Y; Takeuchi H; Oshiro T; Takahashi I; Inutsuka S; Baba H; Kohnoe S; Sugimachi K
Cancer Chemother Pharmacol; 1994; 33(6):445-9. PubMed ID: 8137453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
